Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
Clinical trial NCT06231121 · COMPLETED
Trial details
- NCT number
- NCT06231121
- Sponsor
- Rigshospitalet, Denmark
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-12-01
- Primary completion
- 2024-01-15
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.